



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/564, 33/573, 33/577, C12N 9/02	A1	(11) International Publication Number: WO 99/28752 (43) International Publication Date: 10 June 1999 (10.06.99)
(21) International Application Number: PCT/GB98/03566 (22) International Filing Date: 27 November 1998 (27.11.98) (30) Priority Data: 9725105.2 28 November 1997 (28.11.97) GB (71) Applicant (for all designated States except US): RSR LIMITED [GB/GB]; Avenue Park, Pentwyn, Cardiff CF2 7HE (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): FURMANIAK, Jadwiga [GB/GB]; 35 Havenwood Drive, Thornhill, Cardiff CF4 9HZ (GB). SMITH, Bernard, Rees [GB/GB]; Richmond House, Druidstone Road, Saint Mellons, Cardiff CF3 9XE (GB). (74) Agent: AUSTIN, Hedley, William; Urquhart-Dykes & Lord, Alexandra House, 1 Alexandra Road, Swansea SA1 5ED (GB).		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: DIAGNOSIS OF AUTOIMMUNE ADRENAL DISEASE (57) Abstract Diagnosis of overt, subclinical or potential autoimmune adrenal disease, by contacting a sample of body fluid with: (i) at least one epitope region of 21-hydroxylase which epitope region is essential for binding monoclonal or polyclonal antibodies to 21-hydroxylase and/or autoantibodies to 21-hydroxylase; and (ii) monoclonal or polyclonal antibodies to 21-hydroxylase. The degree of binding of the autoantibodies present in the sample to the relevant epitope region is monitored.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Diagnosis of Autoimmune Adrenal Disease

The present invention relates to diagnosis of overt, subclinical or potential autoimmune adrenal disease. Examples of autoimmune adrenal diseases include Addison's disease (AD) and autoimmune polyglandular syndrome (APS) type I and type II.

More especially, the present invention relates to use of the major autoantigen in autoimmune adrenal disease, human steroid 21-hydroxylase (21-OH) and to the epitopes on the 21-OH molecule reactive with 21-OH autoantibodies (Ab) in a patient's serum. The present invention concerns particular amino acid sequences of the 21-OH peptide, important for 21-OH Ab binding, and methods for using such sequences for diagnosis and prediction of the development of autoimmune adrenal disease.

The adrenal cortex of supra renal glands produce steroid hormones, such as cortisol and aldosterone. In addition, androgens (such as testosterone) are also secreted by the adrenal cortex.

Signs and symptoms of Addison's disease are related to the insufficiency of the adrenal cortex and include low blood pressure, muscle weakness, increased skin pigmentation and electrolyte imbalance. The severity of the symptoms depend on the extent of adrenal failure and if not treated, this disorder will inevitably lead to adrenocortical crisis and subsequent death.

Among the various causes of Addison's disease, the autoimmune origin is currently the most common. Autoantibodies to the adrenal cortex were first described in 1957 using the complement fixation technique. In 1988, an adrenal specific 55 kDa protein was immunoprecipitated from adrenal microsomes using Addison sera. This protein was subsequently shown to be human steroid 21-hydroxylase and identified to be the major adrenal autoantigen in different forms of autoimmune adrenal disease. Measurement of 21-OH Ab is a useful diagnostic tool in cases of suspected or overt adrenal failure and 21-OH Abs can be helpful markers of progression towards autoimmune Addison's disease in patients with other organ-specific autoimmune diseases, such as type I diabetes, especially in children.

Previous studies have shown that autoantibody binding sites on 21-hydroxylase are in the main part conformational and are formed by the central and the C-terminal parts of

-2-

the protein. Three fragments of 21-OH amino acid (AA) sequence (AA 164-356; 272-356 and 338-360) have been reported in US patent 5376533 to be reactive with 21-OH Abs and potentially useful in specific diagnostic assays to identify the autoantibody associated with Addison's disease.

According to the present invention, we have determined that other parts of the 21-hydroxylase sequence are important for autoantibody binding in patients with different forms of autoimmune adrenal disease.

According to the present invention there is provided a method to aid in the diagnosis of overt, subclinical or potential autoimmune adrenal disease, said method comprising:

- (a) providing a sample of body fluid from a subject;
- (b) contacting the sample with
 - (i) at least one epitope region of 21-hydroxylase, which epitope region is either present in said 21-hydroxylase or in a fragment thereof and which epitope region is essential for binding monoclonal or polyclonal antibodies to 21-hydroxylase and/or autoantibodies to 21-hydroxylase; and
 - (ii) monoclonal or polyclonal antibodies to 21-hydroxylase; and
- (c) monitoring the degree of binding of said autoantibodies present in said sample to said epitope region.

Depending on the assay system used, a substantial change in the amount of binding (a substantial increase or substantial decrease) of the autoantibodies to the relevant epitope region indicates that the subject may have autoimmune adrenal disease or be at risk of developing said disease.

In one embodiment of the present invention, the monoclonal or polyclonal antibodies may be immobilised to a solid phase; alternatively, at least one epitope region of 21-hydroxylase may be immobilised to a solid phase. The solid phase may be a magnetic or a non-magnetic material.

The monoclonal or polyclonal antibodies typically comprise any of human antibodies, rodent antibodies, rabbit antibodies or recombinant antibodies or parts or fragments thereof.

The relevant epitope region(s) may be directly labelled; alternatively, in some embodiments, the epitope region(s) may be indirectly labelled (for example, by binding the epitope region(s) to labelled monoclonal antibodies).

According to the present invention, 21-hydroxylase labelled with, for example, ^{125}I is incubated with none, one, or more monoclonal or polyclonal antibodies to 21-hydroxylase. The antibodies are directed to epitope regions on 21-hydroxylase which preferably include amino acids 391 to 405, 406 to 411 and/or amino acids 335 to 339. These monoclonal or polyclonal antibodies bind to the epitope regions on the labelled 21-hydroxylase, thus preventing the subsequent binding of patient serum autoantibodies to the epitope regions. According to the invention, a mixture of labelled 21-hydroxylase (which therefore comprises labelled epitope regions of 21-hydroxylase) and monoclonal or polyclonal antibodies is contacted with the sample of body fluid from a patient (typically with autoantibodies to 21-hydroxylase). The ability of a particular monoclonal or polyclonal antibody to 21-hydroxylase to lower the binding of 21-hydroxylase autoantibodies to 21-hydroxylase indicates the presence of autoantibodies to the same epitope region as the particular monoclonal or polyclonal antibody.

The monoclonal or polyclonal antibody, which itself may be labelled, is selected for reactivity with epitope regions along the amino acid sequence of 21-hydroxylase, the relevant epitope regions preferably comprising amino acid sequence (AA) 391 to 405, (AA) 406 to 411 and/or (AA) 335 to 339.

The method according to the present invention preferably comprises monitoring the reactivity of autoantibodies to 21-hydroxylase in a subject's body fluid (such as serum, whole blood or amniotic fluid) with one or more of the three different epitope regions mentioned above. The reactivity with the three different epitope regions may be monitored individually or in combination.

According to the present invention, the components of the reaction, namely 21-hydroxylase or its relevant epitope region(s), and monoclonal or polyclonal antibodies to 21-hydroxylase, may be labelled with suitable radioisotopic or non-isotopic labels. Suitable isotopic labels include ^{125}I , ^{35}S , ^{14}C and ^3H ; suitable non-isotopic labels include enzymes, dyes, gold, chemiluminescent substances and fluorescent substances.

The reactivity between the various components may be monitored using a variety of methods, such as an enzyme linked immunosorbent assay (ELISA), solid or liquid phase radio-immunoassays (RIA), immunochromatographic assays, immunoprecipitation assays, or the like.

The following examples are used to further illustrate the present invention and are given by way of example only:

Figure 1 is a schematic representation of the restriction enzyme sites on 21-hydroxylase;

Figure 2 is a schematic representation of an experimentally produced series of deletions in cDNA encoding 21-hydroxylase;

Figure 3 is a graphical representation of the effect of Fab or F(ab')₂ fragments of the monoclonal antibodies described in Table 3; M21-OH1 (F(Ab)₂1), M21-OH3(Fab3), M21-OH5(F(Ab)₂5) and a mixture thereof (Fab mixture), on ¹²⁵I-labelled 21-hydroxylase binding to intact 21-hydroxylase autoantibodies in a pool of patient sera; and

Figure 4 is a comparison of amino acid sequences of the epitope regions in human and bovine 21-hydroxylase.

Plasmid Constructions

The full length 21-hydroxylase gene was cloned into pYES2.0 (Invitrogen) (pYES2/21-OH1) downstream of the T7 promoter. Various in frame deletions and truncations of the 21-hydroxylase gene were carried out using different restriction enzyme sites and the modified genes were cloned into pYES3, a derivation of pYES2.0. In addition, construct P21-OH14 was produced using PpumI restriction enzyme.

Table 1 shows the reactivity of full length and modified human steroid 21-hydroxylase with monoclonal antibodies.

Table 1

Construct	Modified 21-OH			Reaction with Monoclonal Antibodies				
	Enzyme Sites Used	Amino acids deleted	Region of deletion	M21-OH1	M21-OH2	M21-OH3	M21-OH4	M21-OH5
P21-OH1	None	None	C-terminal	+	+	+	+	+
P21-OH2	StuI	448-494	C-terminal	+	+	+	+	+
P21-OH3	BstXI	418-494	C-terminal	+	+	+	+	+
P21-OH4	SauI	381-494	C-terminal	-	-	-	-	+
P21-OH12	SauI/BstXI	382-414	Internal	-	-	-	-	+
P21-OH14	PpumI	335-494	C-terminal	-	-	-	-	-
P21-OH5	BprpI	282-494	C-terminal	-	-	-	-	-

Full length 21-hydroxylase cDNA was subcloned into the KpnI site of pTZ18F (pND21-OH1), a derivation of the vector pTZ18R (Pharmacia Biotech). The vector pTZ18F contained a specially designed, unique linker into AccI and HindIII sites which had stop codons in all three frames to ensure translation termination of all inserted genes. A series of 21-hydroxylase gene constructs with small stretches of gene sequence deleted (pND21-OH2-7) were generated from this construct using a Nested Deletion Kit (Pharmacia Biotech) (see Figure 1). These constructs were sequenced by the dideoxy termination method using Sequenase Version 2.0 kit (United States Biochemical) and the M13 (-40) sequencing primer.

Table 2 outlines the various constructs and the reactivity of full length and modified human steroid 21-hydroxylase with monoclonal antibodies.

Table 2

Construct	Amino Acids Deleted	Reaction with Monoclonal Antibodies				
		M21-OH1	M21-OH2	M21-OH3	M21-OH4	M21-OH5
pND21-OH1	None	+	+	+	+	+
pND21-OH2	448-494	+	+	+	+	+
pND21-OH3	412-494	+	+	+	+	+
pND21-OH4	406-494	+	+	-	-	+
pND21-OH5	391-494	-	-	-	-	+
pND21-OH6	360-494	-	-	-	-	+
pND21-OH7	340-494	-	-	-	-	+
pND21-OH8	335-494	-	-	-	-	-

Antibodies to 21-hydroxylase

A panel of 5 mouse monoclonal antibodies (MAbs) raised to human recombinant 21-hydroxylase expressed in *Escherichia coli* was produced at RSR Limited and used in the study. 21-hydroxylase MAb IgG was purified by affinity chromatography on Prosep-A (Bioprocessing Limited) and the purified IgG preparations were treated with either pepsin (Sigma) at an enzyme/protein ratio of 1/10 or mercuripapain (Sigma) at an enzyme/protein ratio of 1/10 and passed through a Prosep-A column to remove any intact IgG or Fc fragment from the Fab or F(ab')₂, respectively. Control IgG and Fab preparations were obtained from a TSH receptor (TSHR) mouse monoclonal antibody (RSR Limited). Rabbit antibody to 21-

hydroxylase from RSR Limited was also used as a control in some experiments. Serum was obtained from 21-hydroxylase Ab positive patients (n=25) with:- APS type I (n=5), APS type II (n=5), isolated Addison's disease (n=5), 21-hydroxylase Ab positive patients with normal adrenal function (potential AD; n=5) and 21-hydroxylase Ab positive patients with impaired adrenal function (subclinical AD; n=5) (see Table 3). Pool positive serum prepared from ten 21-hydroxylase Ab positive patients with AD (21-hydroxylase Ab levels ranging from 7 to 22 units/mL) was used in some experiments. Pool serum from twenty healthy blood donors was used as a negative control.

Immunofluorescence Studies

Classical indirect immunofluorescence tests were carried out using thin cryosections of human and bovine adrenal tissue and fluoresceine isothiocyanate-conjugated anti-mouse IgG.

Analysis of Reactivity of 21-OH MAb with Modified 21-OH Proteins

Modified ³⁵S-labelled 21-hydroxylase proteins containing various deletions and truncations (see Tables 1 and 2, and Figure 1) were produced in the *in vitro* transcription/translation (TnT; Promega) system and were used in an immunoprecipitation assay (IPA) to assess 21-hydroxylase MAb binding. The TnT reactions were carried out with a methionine-free rabbit reticulocyte lysate in the presence of ³⁵S-methionine (10Ci/L; Amersham). The reaction mixture was then passed through a 0.5x16 cm column of Sephadex G50 (Pharmacia), eluted with 150mmol/L Tris buffer pH8.3, containing (per litre) 200mmol of NaCl, 10mL of Tween 20 and 10g of bovine serum albumin (thereafter called Tris buffer); 1mL fractions were collected. The fractions collected were tested for reactivity with 21-OH antibodies by IPA, diluted to give about 30,000 counts/min per 50 μ L and stored in aliquots at -70°C. Synthesis of proteins coded for by the various constructs was assessed by analysis on polyacrylamide gels (9%) in sodium dodecyl sulphate (SDS) followed by autoradiography.

The IPA was carried out with a 96-well filtration plate system incorporating 0.45 μ m (pore size) filters (Multiscreen, Milipore UK Limited) as described before. Aliquots of 50 μ L of ³⁵S-21-OH were incubated with aliquots of antibody (50 μ L) for two hours at room temperature with shaking. To each microtiter well was then added 50 μ L of anti-mouse IgG-agarose (Sigma), diluted 5 fold in Tris buffer and the samples were incubated for one hour more at room temperature with shaking. The plate was then placed on a suction unit

(Millipore UK) and the immune complexes bound to anti-mouse IgG agarose were washed three times with 200 μ L of Tris buffer. After this washing, the bottom of each well was punched out into vials containing 1mL of scintillation liquid (Ultima Gold, Packard) and the radioactivity counted in a scintillation counter. A negative control MAb was included in each assay as well as rabbit 21-hydroxylase Ab as a control. Each experiment was carried out in duplicate and binding to each modified 21-hydroxylase protein was carried out in two separate experiments.

Effects of Fab or F(ab')₂ Preparations on the Binding of Intact Monoclonal 21-OH IgG and 21-OH Abs to ¹²⁵I-21-OH

Further analysis of the epitopes recognised by the 21-hydroxylase MAbs and by 21-hydroxylase Abs was carried out using a technique which exploits the ability of protein A to bind to intact antibody complexed with ¹²⁵I-labelled antigen, but not to Fab or F(ab')₂ bound to labelled antigen.

Fab or F(ab')₂ preparations, at various dilutions, were incubated for seven hours at 4°C with ¹²⁵I-labelled 21-hydroxylase (30,000 cpm/50 μ L). Intact 21-hydroxylase antibodies (either 50 μ L 21-OH MAb IgG or 50 μ L patient sera appropriately diluted in assay buffer) were then added and incubation continued for eighteen hours at 4°C. ¹²⁵I-labelled 21-hydroxylase bound to either intact 21-hydroxylase MAb or 21-hydroxylase Ab were separated by the addition of solid phase protein A.

Computer Analysis of Epitope Region Amino Acid Sequences

The complete cDNA sequences of human and bovine 21-hydroxylase were translated into amino acid sequences using the computer software DNASIS v 2.1 (Hitachi Software Engineering America Limited). The amino acid sequences of the epitope regions in both human and bovine 21-hydroxylase were aligned using the Clustal Method.

Statistical Methods

Statistical analyses were carried out using SPSS for Windows software. The statistical significance of any difference of the effect of Fab or F(ab')₂ preparations on 21-hydroxylase Ab binding between different forms of autoimmune adrenal disease patient groups was determined by Mann-Whitney U Test.

Results

When tested by immunofluorescence, IgGs from all five MAbs reacted with human adrenal tissue and showed positive staining pattern typical for adrenal cortex antibody. MAb 1 and 2 showed positive staining when bovine adrenal tissue was used, whereas MAb 3, 4 and 5 were negative in the immunofluorescence test based on bovine adrenal tissue.

Table 3 shows the characteristics of mouse monoclonal antibodies to 21-hydroxylase.

Table 3

21-OH McAb	Recombinant Immunogen	Subclass/ Light chain	Affinity constants	Epitope Region (AA)	Species of adrenal tissue used in IFT
M21-OH1	21-OH7 (165-379AA del.)	IgG2a / K	$7.0 \times 10^8 \text{ M}^{-1}$	ER1 (391-405)	Human (+) Bovine (+)
M21-OH2	21-OH1-GST (1-494AA)	IgG1 / K	$6.1 \times 10^8 \text{ M}^{-1}$	ER1 (391-405)	Human (+) Bovine (+)
M21-OH3	21-OH1-GST (1-494AA)	IgG1 / K	$2.6 \times 10^8 \text{ M}^{-1}$	ER2 (406-411)	Human (+) Bovine (-)
M21-OH4	21-OH1-GST (1-494AA)	IgG1 / K	$2.0 \times 10^8 \text{ M}^{-1}$	ER2 (406-411)	Human (+) Bovine (-)
M21-OH5	21-OH1-GST (1-494AA)	IgG1 / K	$2.3 \times 10^7 \text{ M}^{-1}$	ER3 (335-339)	Human (+) Bovine (-)

F(ab')₂ fragments were isolated from MAb 1 and 5 whereas Fab fragments were isolated from MAb 3 and the TSHR MAb and these preparations were used in the binding inhibition studies with all five MAbs. These studies showed that the 21-hydroxylase MAbs could be classified into three groups.

Group I:- MAb 1 and 2 which bound to the same epitope region (ER1) on 21-hydroxylase;

Group II:- MAb 3 and 4 which both bound to a different region (ER2); and

Group III:- MAb 5 which recognised a third region (ER3).

Inhibition studies using pooled patient sera and Fab or F(ab')₂ preparations representative of each MAb group (MAb 1, 3 and 5) suggested that 21-hydroxylase Abs recognise epitopes on 21-hydroxylase similar to those recognised by the MAbs (Figure 2).

Binding of the Ab in pooled patient sera to ¹²⁵I-21-hydroxylase was only slightly inhibited (up to 15%) by MAb 1 F(ab')₂, but by up to 52% with MAb 3 Fab and up to 74%

by MAb 5 F(ab')₂ (see Figure 2). A combination of three Fab or F(ab')₂ (Fab mixture) inhibited 21-hydroxylase binding by Ab in a pooled patient sera by up to 88%. The control Fab inhibited binding of patient Ab to ¹²⁵I-21-hydroxylase up to 15% (Figure 2).

Fab or F(ab')₂ preparations from Mab1, 3 and 5 were also used in inhibition studies with individual 21-hydroxylase Ab positive sera. The results of these studies are shown below in Table 4 and are expressed as a percent inhibition of ¹²⁵I-21-hydroxylase binding relative to binding of Ab in the absence of Fab or F(ab')₂ preparations.

Table 4

Patient	Sex	Age	Diagnosis	ACA titre	21-OH Ab (unit/ml)	% Inhibition of ¹²⁵ I-21-OH binding			
						F(ab') ₂ 1	Fab3	F(ab') ₂ 5	Fab Mixture
						(100µg/ml)	(100µg/ml)	(100µg/ml)	(200µg/ml)
1	F	45	APS I	>320	67.5	23	48	77	93
2	F	44	APS I	320	3.3	3	53	85	85
3	F	39	APS I	80	32.3	21	75	84	95
4	F	15	APS I	80	41.2	5	43	82	85
5	M	33	APS I	+	15.1	4	68	85	87
6	F	53	APS II	256	10.7	50	45	53	87
7	F	42	APS II	516	71.2	14	51	78	81
8	F	39	APS II	+	15.3	4	66	82	89
9	F	50	APS II	+	22.5	12	72	85	91
10	F	51	APS II	+	32.8	16	27	92	92
11	M	27	AD	320	20	0	67	83	92
12	M	31	AD	320	44.4	2	46	80	90
13	F	28	AD	+	78.9	30	27	35	67
14	F	-	AD	+	22	47	42	52	90
15	F	-	AD	+	10.4	8	36	75	80
16	F	35	potential AD	>320	23.4	15	38	73	93
17	F	29	potential AD	>320	17.4	16	65	82	93
18	F	23	potential AD	40	46.4	16	67	79	94
19	F	63	potential AD	4	15.7	22	73	75	92
20	M	25	potential AD	80	45.7	15	67	85	93
21	F	55	subclinical AD	320	27	13	41	83	92
22	F	33	subclinical AD	512	34.8	22	47	79	87
23	F	26	subclinical AD	640	76.3	14	63	75	87
24	M	32	subclinical AD	64	42.4	6	66	74	90
25	F	66	subclinical AD	4	16.0	3	47	72	80

ACA titre = adrenal cortex autoantibody (measured by immunofluorescence)
 21-OHAb = 21-OH autoantibodies levels measured by immunoprecipitation assay according to Tanaka et al; J. Clin Endocr. Metab 82 (1997) 1440-1446.

In the majority of patients, the binding of Ab to ^{125}I -21-OH was not or only partially inhibited by MAb 1 F(ab')_2 with a mean inhibition of $15\% \pm 12.7$ (mean $\pm$ SD, $n=25$; range 0-50%). However in the case of sera from 3 patients (1 in the APS type II group and 2 in the AD group) MAb 1 F(ab')_2 caused inhibition of Ab binding of 50%, 30% and 47%, respectively (see Table 4). MAb 3 Fab resulted in inhibition of Ab binding to ^{125}I -21-hydroxylase in all 25 patient sera studied with a mean inhibition of $54\% \pm 14.5$ (mean $\pm$ SD, $n=25$; range 27-75%) (see Table 4).

MAb 5 F(ab')_2 also inhibited the Ab binding to ^{125}I -21-hydroxylase in all 25 patient sera with a mean inhibition of $76\% \pm 12.4$ (mean $\pm$ SD, $n=25$; range 35-92%) (see Table 4).

A combination of the three Fab or F(ab')_2 preparations resulted in essentially complete inhibition of Ab binding to ^{125}I -21-hydroxylase in 24 out of 25 patients with a mean inhibition of $89.5\% \pm 4.6$ (mean $\pm$ SD, $n=24$; range 80-95%). However, in the case of one patient in the AD group the combination of three Fab and F(ab')_2 preparations resulted in only 67% inhibition (see Table 4).

There were no statistical differences in the effect of each Fab or F(ab')_2 fragments on Ab binding between the different patient groups ($p > 0.05$).

However when a combination of all the three Fab or F(ab')_2 preparations were used, there were statistically significant differences between the inhibition of Ab binding of the APS type II group and the potential AD group ($p=0.01$), the AD group and the potential AD group ($p=0.01$), and the subclinical AD group and the potential AD group ($p=0.01$); there were no statistically significant differences between the other groups ($p > 0.05$).

In the IPA based on ^{35}S -labelled 21-hydroxylase, all five MAbs reacted with full length 21-hydroxylase and with 21-hydroxylase truncated at either amino acid 448 or 418 (from constructs p21-OH1, p21-OH2 and p21-OH3; Table 1). In addition, MAb 5 reacted with 21-hydroxylase truncated at amino acid 381 (from construct p21-OH4) and with 21-hydroxylase with the internal deletion 382-414 amino acids (from construct p21-OH12; Table 1). None of the 21-hydroxylase MAbs bound to 21-OH truncated at either amino acid 335 or amino acid 282 (from constructs p21-OH14 and p21-OH5, respectively; see Table 1).

Further studies were carried out using modified 21-hydroxylase proteins, with smaller stretches of amino acids deleted. All the 21-hydroxylase MAbs reacted with 21-hydroxylase with the amino acids 494-412 deleted (from constructs pND21-OH2 and pND21-OH3; see Table 2). MAb 1, 2 and 5 reacted with 21-hydroxylase with the amino acids 494-406 deleted (from construct pND21-OH4; see Table 2) whereas MAb 3 and 4 did not react with this modified protein (see Table 2). MAb 1-4 did not react with modified 21-hydroxylase proteins truncated at amino acids 391, 360, 340 and 335 (from constructs pND21-OH5-8, respectively; Table 2). In contrast, MAb 5 bound to 21-hydroxylase proteins truncated at amino acid 391, 360 and 340 but not to 21-hydroxylase truncated at amino acid 335 (Table 2).

Consequently, amino acids 391-405, defined as ER1, appeared important for binding of MAb 1 and MAb 2. Amino acids 406-411, defined as ER2, appeared important for binding of MAb 3 and MAb 4 and amino acids 335-339, defined as ER3, appeared important for binding of MAb 5.

Computer analysis was carried out on the amino acid sequences of human and bovine 21-hydroxylase, to compare the sequences in the epitope regions ER1, 2 and 3. ER1 (AA 391-405) recognised by MAb 1 and MAb 2, was found to be 87% homologous, with 2 amino acid changes; arginine at position 400 in human 21-hydroxylase is changed to glutamine in bovine 21-hydroxylase and tryptophan at position 405 in human 21-hydroxylase is changed to arginine in bovine 21-hydroxylase (Figure 3). ER2 (AA 406-411) recognised by MAb 3 and MAb 4, was found to be 100% homologous. ER3 (AA 335-339) recognised by MAb 5, was found to be 80% homologous, with only 1 amino acid different between human and bovine 21-hydroxylase; proline at position 335 in human 21-hydroxylase is changed to threonine in bovine 21-hydroxylase (Figure 3).

Conclusions

Consequently, we have identified three stretches of 21-hydroxylase amino acid sequence located in the C-terminal part of the protein which are essential for binding Mabs 1 to 5. As Fab or F(ab')₂ fragments prepared from these monoclonal antibodies almost completely inhibited binding of 21-hydroxylase autoantibodies in 24 out of 25 of the sera studied, the same stretches of amino acids must also be essential for autoantibody binding. Autoantibody binding was inhibited to the greatest

extent with the MAb 5 F(ab')₂, which suggests that ER3 (AA 335-339) is the most important, autoantigenic epitope in the majority of patient sera. Studies with Fab or F(ab')₂ preparations from MAb 1 and MAb 3 indicated that ER1 (AA 391-405) is less important than ER3 (AA 335-339) and ER2 (AA 406-411).

Similar results were obtained when 21-hydroxylase Ab from patients with different forms of autoimmune disease were studied. 21-hydroxylase Ab epitopes dependent on AA 335-339 (ER3) and AA 406-411 (ER2) are specific for human 21-hydroxylase and 21-hydroxylase Ab directed to these epitopes do not react with bovine adrenal tissue in immunofluorescence tests. Analyses of differences in the reactivity of MAb with human and bovine adrenal tissue in immunofluorescence studies and the differences in the amino acid sequences of human and bovine 21-hydroxylase suggest that proline 335 is important in forming the major 21-hydroxylase Ab binding site(s).

Overall, these studies show that:

1. The binding of 21-hydroxylase autoantibodies is dependent on at least three different epitopes in the C-terminal part of 21-hydroxylase (AA 335-339, 391-405 and 406-411);
2. Two of these epitopes (one dependent on AA 335-339 and the other dependent on AA 406-411) are human 21-hydroxylase specific and a third (AA 391-405) is present on both human and bovine 21-hydroxylase.

Claims:

1. A method to aid in the diagnosis of overt, subclinical or potential autoimmune adrenal disease, said method comprising:
 - (a) providing a sample of body fluid from a subject;
 - (b) contacting the sample with
 - (i) at least one epitope region of 21-hydroxylase, which epitope region is either present in said 21-hydroxylase or in a fragment thereof and which epitope region is essential for binding monoclonal or polyclonal antibodies to 21-hydroxylase and/or autoantibodies to 21-hydroxylase; and
 - (ii) monoclonal or polyclonal antibodies to 21-hydroxylase; and
 - (c) monitoring the degree of binding of said autoantibodies present in said sample to said epitope region.
2. A method according to claim 1, wherein said monoclonal or polyclonal antibodies are immobilised to a solid phase.
3. A method according to claim 1, wherein said at least one epitope region of 21-hydroxylase is immobilised to a solid phase.
4. A method according to any of claims 1 to 3, wherein said epitope region of 21-hydroxylase comprises:
 - (i) 21-hydroxylase amino acids 391 to 405; and/or
 - (ii) 21-hydroxylase amino acids 406 to 411; and/or
 - (iii) 21-hydroxylase amino acids 335 to 339.
5. A method according to any of claims 1 to 4, wherein said monoclonal or polyclonal antibodies to 21-hydroxylase comprise:
 - (i) at least one monoclonal or polyclonal antibody to the epitope region of 21-hydroxylase comprising amino acids 391 to 405; and/or

- (ii) at least one monoclonal or polyclonal antibody to the epitope region of 21-hydroxylase comprising amino acids 406 to 411; and/or
 - (iii) at least one monoclonal or polyclonal antibody to the epitope region of 21-hydroxylase comprising amino acids 335 to 339.
6. A method according to claim 4 or 5, wherein said epitope region is a human or bovine tissue derived fragment comprising said amino acids 391 to 405.
 7. A method according to any of claims 4 to 5, wherein said epitope region is a human derived fragment comprising amino acids 406 to 411.
 8. A method according to any of claims 4 to 7, wherein said epitope region is a human derived fragment comprising amino acids 335 to 339.
 9. A method according to any of claims 1 to 8, wherein said antibodies comprise any of human antibodies, rodent antibodies or recombinant antibodies, or parts or fragments thereof.
 10. A method according to any of claims 1 to 9, wherein said monitoring comprises using an enzyme linked immunosorbent assay (ELISA).
 11. A method according to any of claims 1 to 9, wherein said monitoring comprises using a radioimmunoassay (RIA).
 12. A method according to any of claims 1 to 9, wherein said monitoring comprises using an immunoprecipitation assay.
 13. A method according to any of claims 1 to 9, wherein said monitoring comprises using an immunochromatographic assay.

14. A method according to any of claims 1 to 13, wherein said autoimmune adrenal disease comprises Addison's disease or autoimmune polyglandular syndrome.
15. A method according to any of claims 1 to 14, wherein said body fluid comprises serum.
16. A method according to any of claims 1 to 14, wherein said body fluid comprises whole blood.
17. A method according to any of claims 1 to 14, wherein said body fluid comprises amniotic fluid.
18. A method according to any of claims 1 to 14, wherein said body fluid comprises plasma.
19. A method according to any of claims 1 to 18, wherein said epitope region and/or said monoclonal or polyclonal antibody includes either an isotopic or non-isotopic label.
20. A method according to claim 19, wherein said isotopic label comprises ^{125}I .
21. A method according to claim 19, wherein said non-isotopic label includes a dye label or an enzyme label (using an enzyme such as alkaline phosphatase or horseradish peroxidase).

FIGURE 1




FIGURE 2




FIGURE 3





FIGURE 4



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/03566

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/564 G01N33/573 G01N33/577 C12N9/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 376 533 A (N.K. MACLAREN ET AL.) 27 December 1994 see claims 1,2; examples 1-3	1-3,9-21
Y	---	1-21
Y	WO 94 25604 A (RSR LIMITD) 10 November 1994 see page 19, line 1 - page 24, line 3; claim 34 -----	1-21



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 May 1999

Date of mailing of the international search report

11/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bohemen, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/03566

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5376533	A	27-12-1994	NONE		
WO 9425604	A	10-11-1994	AU	6661094 A	21-11-1994
			JP	9500008 T	07-01-1997
			US	5705400 A	06-01-1998